Have a feature idea you'd love to see implemented?
Let us know!
ALLK Allakos Inc
Price (delayed)
$1.25
Market cap
$111.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.04
Enterprise value
$136.94M
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab
Highlights
Allakos's debt has decreased by 8% YoY and by 2.4% from the previous quarter
The company's quick ratio has surged by 69% QoQ but it fell by 30% YoY
ALLK's EPS is down by 33% year-on-year but it is up by 13% since the previous quarter
The equity has dropped by 67% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of ALLK
Market
Valuations
Earnings
Shares outstanding
89.34M
Market cap
$111.68M
Enterprise value
$136.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$178.75M
EBIT
-$186.47M
EBITDA
-$179.88M
Free cash flow
-$105.47M
Per share
Balance sheet
Liquidity
EPS
-$2.04
EPS diluted
-$2.04
Free cash flow per share
-$1.18
Book value per share
$0.82
Revenue per share
$0
TBVPS
$1.4
Total assets
$124.43M
Total liabilities
$51.69M
Debt
$35.71M
Equity
$72.74M
Working capital
$81.17M
Debt to equity
0.49
Current ratio
6.08
Quick ratio
5.8
Net debt/EBITDA
-0.14
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-101.9%
Return on equity
-166.5%
Return on invested capital
-128.8%
Return on capital employed
-171.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLK stock price
How has the Allakos stock price performed over time
Intraday
-1.57%
1 week
-3.1%
1 month
39.79%
1 year
-54.21%
YTD
-54.21%
QTD
91.37%
Financial performance
How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$186.44M
Net income
-$178.75M
Gross margin
N/A
Net margin
N/A
The net income has grown by 13% from the previous quarter but it has contracted by 8% YoY
The operating income has grown by 13% from the previous quarter but it has contracted by 5% YoY
Growth
What is Allakos's growth rate over time
Valuation
What is Allakos stock price valuation
P/E
N/A
P/B
1.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS is down by 33% year-on-year but it is up by 13% since the previous quarter
The equity has dropped by 67% year-on-year and by 13% since the previous quarter
ALLK's price to book (P/B) is 64% less than its 5-year quarterly average of 4.3 but 41% more than its last 4 quarters average of 1.1
Efficiency
How efficient is Allakos business performance
ALLK's return on equity has dropped by 167% year-on-year and by 17% since the previous quarter
The return on assets has dropped by 105% year-on-year and by 6% since the previous quarter
The ROIC has plunged by 96% YoY
Dividends
What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLK.
Financial health
How did Allakos financials performed over time
Allakos's total assets is 141% more than its total liabilities
The current ratio has soared by 70% QoQ but it has decreased by 35% YoY
The company's quick ratio has surged by 69% QoQ but it fell by 30% YoY
Allakos's debt is 51% less than its equity
ALLK's debt to equity has soared by 172% YoY and by 11% from the previous quarter
The equity has dropped by 67% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.